The results of the SIPPET (Survey of Inhibitors in Plasma-Products Exposed Toddlers) study were published last week as an abstract in advance of a plenary session presentation at the American Society of Hematology (ASH) conference in December.
SIPPET was a randomized study, which took place between January 2010 and December 2014, and included data on 251 children <6 years of age with severe hemophilia A from 14 countries in Africa, North and South America, Asia and Europe.
The purpose of the study was to compare the incidence of factor VIII (FVIII) inhibitors with plasma-derived FVIII concentrates versus recombinant FVIII concentrates in previously untreated patients (PUPs) with severe hemophilia. The abstract suggests that in PUPs, the risk of developing an inhibitor within the first 50 exposure days when using recombinant factors is higher than when using plasma-derived factor concentrates.
The results of this study may prove to be significant to our community. The National Hemophilia Foundation’s (NHF's) Medical and Scientific Advisory Council (MASAC) will review the ASH presentation and published paper when available. NHF will update the community of MASAC recommendations as they become available.
